Biotech newsletter subscribers are updated on various industry news, including Biogen acquiring Human Immunology Biosciences for $1.15 billion, FDA evaluating Guardant’s colon cancer test, and AstraZeneca’s plans to double revenue by 2030. Maryland establishes a drug affordability board, studying the benefits of anti-seizure drugs for alcohol-associated liver disease, and the challenges of mass-producing an H5N1 bird flu vaccine. CDC maintains flu surveillance due to the bird flu threat, senators discuss patent reforms, and Pfizer faces scrutiny in a tax probe. Overall, the biotech industry remains dynamic, with advancements and challenges in drug development and regulation.
Source link
Biogen, Guardant, AstraZeneca, H5N1 vaccine
